Affiliated Hospital to Academy of Military Medical Sciences and Beijing JD Biotech

Beijing JD Biotech is a Chinese biotechnology company specializing in the development of advanced immunotherapies, with a primary focus on Chimeric Antigen Receptor T-cell (CAR-T) treatments. The company operates through a long-standing strategic collaboration with the Affiliated Hospital to the Academy of Military Medical Sciences (also known as the 307th Hospital of the PLA) to conduct clinical research. Their pipeline includes several CAR-T candidates targeting hematological malignancies by addressing antigens such as CD19, CD20, and CD22. By leveraging proprietary cell engineering technologies and clinical expertise from its hospital partnership, Beijing JD Biotech aims to provide novel solutions for refractory and relapsed cancers. The entity is frequently cited in clinical trial registries for its early-phase studies in leukemia and lymphoma within the Chinese market.